Advancements in the Pharmaceutical Oncology

1
Advancements in the Pharmaceutical Oncology
2

• About Pinnacle Lifescience

• Pinnacle Life Science is a 100 subsidiary of
  Indias most trusted pharmaceutical company Aarti
  Drugs Ltd (ADL) and forms part of 1.5 billion
  conglomerate of the esteemed Aarti Group of
  Industries.
• With 35 years of healthcare commitment through
  Aarti Drugs, Pinnacle has made its presence in
  nearly 90 countries. Treading carefully on the
  path of efficient healthcare, the
  state-of-the-art manufacturing facility is
  designed to produce formulations that meet
  international quality standards and stringent
  regulatory compliances to trade beyond borders.
• With significant expansion in RD, Manufacturing
  Marketing capabilities, we are poised for an
  accelerated growth.

3

• Advancements in the Pharmaceutical Oncology

• Cancer therapy continues to progress. Efficient
  prevention, faster detection, a greater
  understanding of the causing genetic
  abnormalities, and the discovery of novel
  medicines all contribute to a drop in cancer
  mortality year in and year out. Conversely,
  certain malignancies continue to be resistant to
  all therapy despite increasing accomplishments.
  There is a major medical need to get better
  medicines to these patients more rapidly and
  efficiently in terms of time, cost, and the
  likelihood of success. Oncology clinical drug
  development innovation is required to allow more
  effective and efficient development of novel
  cancer therapeutics and provide patients
  especially those with rare cancers- with access
  to new medications much sooner.

4

• Advancements in the Pharmaceutical Oncology

• However, beginning in the late 1980s, there was a
  surge in the knowledge of the molecular defects
  that produce and perpetuate the tumours distinct
  traits. This molecular knowledge has led to the
  creation of targeted medicines and therapeutic
  interventions, each tailored to a certain kind of
  genetic abnormality.

5

• Advancements in the Pharmaceutical Oncology

• IPrecision medicine in cancer began with the
  discovery of targeted medicines. This medical
  strategy entails identifying the molecular
  lesions present in a tumour and then choosing
  therapies targeting these lesions precisely.
  Precision medicine strives to provide cancer
  patients with the most suitable treatment the
  right drug, for the right patient, at the right
  time, and the right dose. This is especially
  relevant since individuals with comparable tumour
  form and function, known as tumour histology,
  may have patient subpopulations due to various
  genetic abnormalities in their tumours.
• Poverty, late and inadequate cancer diagnosis,
  and a lack of medical coverage have been
  identified as the top three severe obstacles
  cancer patients face in various situations.

6

• Advancements in the Pharmaceutical Oncology

• Scientific improvements must be linked with
  dynamic public-private partnerships and a clear
  explanation of our aims to overcome the
  challenges in our path to providing sustainable
  cancer treatment to all. To fully embrace
  value-based medicine, we must change our focus
  from paying per pill to long-term benefits
  across a patients lifetime benefits to the
  patient, the healthcare system, and society. It
  also entails breaking down divisions in
  healthcare budgets and exploring ways to share
  expenses and savings. This means, for example,
  that if a pharmaceutical minimises
  post-chemotherapy hospitalisations, we have the
  freedom to support this treatment not just from
  the pharmacy budget but also from the hospital
  budget savings associated with this favourable
  outcome.

7

• Advancements in the Pharmaceutical Oncology

• Corporations may find it necessary to raise
  resources for educational initiatives to ensure
  that all stakeholders know better about novel
  financing and reimbursement methods that will
  ensure medications reach the patients who need
  them. We can determine which funding options are
  appropriate based on the disease area and
  demographic segment by working together. Finally,
  authorities throughout the globe must transform
  the way they think about and communicate about
  cancer to effectively assist patients and their
  families. Cancer research spending rates differ
  over the world, especially among underdeveloped
  countries.
• More information https//www.pinnaclelifescience.
  com/2021/12/03/advancements-in-the-pharmaceutical-
  oncology/

8
Contact Us
Address Mahendra Industrial Estate, Ground
Floor, Plot No. 109D, Road No 29, Sion(E)
Mumbai-400022, India. Phone No  91 (22)
24019025 Email export.pinnacle_at_aartidrugs.com Sit
e www.pinnaclelifescience.com
9
(No Transcript)